Wordt geladen...
Research update on the anticancer effects of buparlisib
Buparlisib is a highly efficient and selective PI3K inhibitor and a member of the 2,6-dimorpholinopyrimidine-derived family of compounds. It selectively inhibits four isomers of PI3K, PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ, by competitively binding the lipid kinase domain on adenosine 5′-triphosphate (ATP),...
Bewaard in:
| Gepubliceerd in: | Oncol Lett |
|---|---|
| Hoofdauteurs: | , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
D.A. Spandidos
2021
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7885152/ https://ncbi.nlm.nih.gov/pubmed/33717263 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2021.12527 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|